•  
  •  
 

Subject Area

Obstetrics and Gynecology

Article Type

Letter to the Editor

Abstract

Objective To study the lipid profile in hepatitis C virus (HCV) patients before and after treatment with daclatasvir (DAV)+sofosbuvir (SOF)±ribavirin (RBV) to determine the effect of virus clearance on the lipid profile. Background Chronic HCV infection is associated with lipid and lipid protein metabolism disorders. There is a marked increase in serum low-density lipoprotein-cholesterol (LDL-C) in HCV-infected patients treated with SOF and RBV. Participants and methods A total of 100 chronic hepatitis C patients were included in a case–control study from February 2017 to August 2017. Twenty healthy individuals volunteered as a control group. Lipid profile changes were analyzed at baseline, after the end of treatment, and 12 weeks after treatment. Results Before treatment, the levels of serum LDL-C, cholesterol and triglycerides (TGs) were significantly lower in patients than the controls. At the end of treatment and 12 weeks after treatment with DCV + SOF + RBV, there was a significant increase in serum LDL-C, high-density lipoprotein-cholesterol, cholesterol, and TGs (P = 0.0001, 0.0001, 0.0001, and 0.007), respectively, and there was also a significant increase in patients treated with DCV + SOF (P = 0.035, 0.036, 0.01, and 0.0001), respectively. 100% of the treated patients achieved a sustained viral response (week 24). Conclusion Eradication of HCV was associated with an increase in the serum level of total cholesterol, TGs, LDL-C, and high-density lipoprotein-cholesterol; so follow up of the patient's lipid profile after Hepatitis C virus treatment is very important to avoid hyperlipidemia which is a risk for atherosclerotic heart disease.

Download

Share

COinS